The Stork® OTC is Now Available to Consumers at a New Lower Price

PITTSBURGH–(BUSINESS WIRE)–Rinovum® Women’s Health announced
The Stork® OTC, the only FDA-cleared,
over-the-counter treatment device designed to optimize the chances of
at-home conception using the cervical cap insemination technique, is now
available to consumers at 25 percent less. The price reduction aligns
with the company mission to provide an affordable, reliable and quality
solution that aids in conception.

By implementing major manufacturing improvements, Rinovum Women’s
Healthcare now offers The Stork OTC at a significantly reduced price to
help optimize the chances of at-home conception for one in six couples
struggling with infertility1. These manufacturing
improvements include reduction of redundant components, improved
manufacturing capabilities, and the creation of supply chain
efficiencies that reduced labor and time expenses. And, because Rinovum
Women’s Health goal is to simply help others, the company is taking less
profit, putting money back into their consumers’ pockets to invest in
their families.

“Rinovum Women’s Health created the Stork OTC home conception device as
an option for women and couples to try before attempting assisted
reproductive treatments, and to bridge the gap between natural
intercourse and fertility treatments,” stated Stephen Bollinger,
president and chief executive officer of Rinovum Women’s Health, and
co-creator of the device. “Our goal is to make The Stork OTC accessible
and affordable so couples can increase their chance of becoming pregnant
within the privacy and comfort of their home.”

The Stork OTC uses a clinically proven technique of cervical cap
insemination, once only available at a doctor’s office – and at a much
lower cost. It’s an option that goes beyond basic ovulation tracking and
lets consumers take back control of their journey.

“We know how stressful and costly the path to parenthood can be. Many in
our company have been down some part of the fertility path to build
their own families, so we understand how difficult the process can be,”
Bollinger stated. “Many consumers expressed their need for an
alternative to current expensive and invasive fertility treatment
options that are unattainable for most. We heard them loud and clear,
and wanted to help by offering The Stork OTC at an even lower cost.”

Though clinical reproductive treatments abound, they are often complex,
drawn-out procedures that can cost couples upwards of $10,000. The Stork
OTC offers an elegantly simple way to optimize chances for conception,
in the privacy of a home, now at an even better price point that is far
less costly than invasive procedures.

About The Stork Ib2C, Inc., A Rinovum Women’s Health Company

Rinovum Women’s Health is a privately held women’s health company
dedicated to bringing products to the market that will enhance women’s
lives and empower them to take charge of their health. The Stork Ib2C,
Inc., A Rinovum Women’s Health Company, launched its flagship product,
The Stork® OTC, which is a conception device for reproductive health to
assist in natural fertility and conception in the privacy of the
patient’s home. Rinovum Women’s Health aims to support the development
of products that are easy-to-use and safe, as well as a more economical
way for a couple to address common fertility diagnoses. For more
information about Rinovum Women’s Health, The Stork Ib2C, Inc., and The
Stork OTC visit

1National Institutes of Health, National Institute of Child
Health and Human Development


The Stork Ib2C, Inc, A Rinovum Women’s Health Company
Clements, 724-241-8936
Swiantek, 724-880-1122